Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xencor Inc (NQ: XNCR ) 21.26 +0.25 (+1.19%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Xencor Inc < Previous 1 2 3 4 5 6 Next > Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 December 15, 2021 Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: Via Benzinga Xencor: Q3 Earnings Insights November 08, 2021 Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their... Via Benzinga Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting December 12, 2021 From Xencor, Inc. Via Business Wire Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal November 27, 2021 In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to... Via Talk Markets Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine November 24, 2021 Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's... Via Benzinga Topics Lawsuit Exposures COVID-19 Financial Legal Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma November 22, 2021 Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a... Via Benzinga Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor November 21, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at Upcoming Investor Conferences November 19, 2021 From Xencor, Inc. Via Business Wire Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting November 12, 2021 From Xencor, Inc. Via Business Wire Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting November 12, 2021 From Xencor, Inc. Via Business Wire Novartis Dumps Another Bispecific Candidate From Xencor Deal November 09, 2021 Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The... Via Benzinga Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript November 08, 2021 XNCR earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 November 08, 2021 From Xencor, Inc. Via Business Wire Preview: Xencor's Earnings November 05, 2021 Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting November 04, 2021 From Xencor, Inc. Via Business Wire Earnings Scheduled For November 8, 2021 November 08, 2021 Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... Via Benzinga Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium November 03, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at Upcoming Investor Conferences November 02, 2021 From Xencor, Inc. Via Business Wire Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 November 01, 2021 From Xencor, Inc. Via Business Wire JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody October 04, 2021 Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global... Via Benzinga Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies October 04, 2021 From Xencor, Inc. Via Business Wire Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting October 01, 2021 From Xencor, Inc. Via Business Wire Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference September 20, 2021 From Xencor, Inc. Via Business Wire The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration August 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Return on Capital Employed Insights for Xencor August 20, 2021 After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total... Via Benzinga Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China August 17, 2021 Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater... Via Benzinga Stocks That Hit 52-Week Lows On Friday August 20, 2021 On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-... Via Benzinga Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript August 04, 2021 XNCR earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Xencor Reports Second Quarter 2021 Financial Results August 04, 2021 From Xencor, Inc. Via Business Wire The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings August 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
